DexCom (DXCM) Price Target Increased to $160.00 by Analysts at Stephens

DexCom (NASDAQ:DXCM) had its price target upped by stock analysts at Stephens from $170.00 to $160.00 in a research note issued to investors on Wednesday, The Fly reports. The brokerage currently has an “overweight” rating on the medical device company’s stock. Stephens’ price objective would indicate a potential upside of 8.49% from the stock’s previous close.

DXCM has been the subject of several other research reports. Morgan Stanley upped their price target on DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 11th. Oppenheimer set a $125.00 price target on DexCom and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Piper Jaffray Companies upped their price target on DexCom to $150.00 and gave the stock an “overweight” rating in a research note on Thursday, August 2nd. Bank of America upped their price target on DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Berenberg Bank upgraded DexCom from a “hold” rating to a “buy” rating and set a $140.00 price target for the company in a research note on Monday, August 6th. Eight equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. DexCom presently has an average rating of “Buy” and a consensus price target of $132.50.

Shares of NASDAQ DXCM opened at $147.48 on Wednesday. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69. DexCom has a one year low of $49.17 and a one year high of $152.14. The stock has a market capitalization of $11.74 billion, a price-to-earnings ratio of -254.28 and a beta of 0.60.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.29. The company had revenue of $266.70 million during the quarter, compared to the consensus estimate of $242.72 million. DexCom had a negative return on equity of 3.08% and a net margin of 4.72%. The company’s revenue for the quarter was up 44.5% on a year-over-year basis. On average, equities research analysts anticipate that DexCom will post -0.49 EPS for the current fiscal year.

In related news, Director Mark G. Foletta sold 1,000 shares of the business’s stock in a transaction dated Friday, August 24th. The stock was sold at an average price of $137.50, for a total transaction of $137,500.00. Following the completion of the transaction, the director now owns 4,052 shares of the company’s stock, valued at approximately $557,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Patrick Michael Murphy sold 2,372 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.69, for a total value of $340,832.68. The disclosure for this sale can be found here. Insiders have sold a total of 157,892 shares of company stock valued at $21,864,030 in the last three months. 1.80% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. Morgan Stanley lifted its position in shares of DexCom by 16.3% during the 2nd quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after purchasing an additional 705,072 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of DexCom by 67,520.1% during the 2nd quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock worth $46,948,000 after purchasing an additional 493,572 shares during the last quarter. Waddell & Reed Financial Inc. lifted its position in shares of DexCom by 164.8% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after purchasing an additional 354,331 shares during the last quarter. Columbus Circle Investors lifted its position in shares of DexCom by 192.3% during the 2nd quarter. Columbus Circle Investors now owns 532,489 shares of the medical device company’s stock worth $50,576,000 after purchasing an additional 350,339 shares during the last quarter. Finally, Ardevora Asset Management LLP acquired a new position in shares of DexCom during the 3rd quarter worth about $36,654,000.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Inflation

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply